A Prospective, Multicenter, and Exploratory Study of CMGV in the Treatment of Recurrent Adult AML and MDS-EB-2/Elder AML

This study is testing a treatment called CMGV in people with relapsed or hard-to-treat acute myeloid leukemia (AML) — a cancer of the blood and bone marrow — or a related condition called MDS with excess blasts type 2. This trial focuses on patients who are older or whose AML has specific features that make it more difficult to treat with standard therapies. **You may be eligible if:** - You are between 18 and 75 years old - You have been diagnosed with AML or MDS with high-risk features (such as treatment-related AML, prior MDS, specific genetic/chromosomal abnormalities, prior chronic blood disorders, or age 60 and older) - You are in generally good health (able to function independently, no major organ problems) - Your expected survival is at least 3 months - Your liver and kidney function meet required levels **You may NOT be eligible if:** - You are in very poor general health (ECOG score of 3 or more) or have major medical conditions - Your liver or kidney function is significantly impaired - You have an active serious infection Talk to your doctor to see if this trial is right for you.